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Currently, there are no effective biomarkers for ovarian cancer prognosis or prediction of therapeutic response. The objective of this
study was to examine a panel of 10 serum biochemical parameters for their ability to predict response to chemotherapy, progression
and survival of ovarian cancer patients. Sera from ovarian cancer patients were collected prior and during chemotherapy and were
analysed by enzyme-linked immunosorbent assay for CA125, kallikreins 5, 6, 7, 8, 10 and 11, B7-H4, regenerating protein IV and
Spondin-2. The odds ratio and hazard ratio and their 95% confidence interval (95% CI) were calculated. Time-dependent receiver-
operating characteristic (ROC) curves were utilised to evaluate the prognostic performance of the biomarkers. The levels of several
markers at baseline (c0), or after the first chemotherapy cycle (rc1), predicted chemotherapy response and overall or progression-free
survival in univariate analysis. A multiparametric model (c0 of CA125, KLK5, KLK7 and rc1 of CA125) provided predictive accuracy
with area under the ROC curve (AUC) of 0.82 (0.62 after correction for overfitting). Another marker combination (c0 of KLK7,
KLK10, B7-H4, Spondin-2) was useful in predicting short-term (1-year) survival with an AUC of 0.89 (0.74 after correction for
overfitting). All markers examined, except KLK7 and regenerating protein IV, were powerful predictors of time to progression (TTP)
among chemotherapy responders. Individual and panels of biomarkers from the kallikrein family (and other families) can predict
response to chemotherapy, overall survival, short-term (1-year) survival, progression-free survival and TTP of ovarian cancer patients
treated with chemotherapy.
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Ovarian cancer is the most lethal gynaecologic malignancy,
ranking fifth in mortality among all carcinomas in women
(American Cancer Society, 2007; Jemal et al, 2007). The high
mortality rate has not improved substantially over the past years,
despite our better understanding of the molecular events under-
lying malignancy and the availability of improved surgical
techniques and novel chemotherapeutic agents (Marsden et al,
2000; American Cancer Society, 2007). The major reason for the
poor prognosis of ovarian cancer is that over 75% of patients have
disseminated disease (International Federation of Gynaecology
and Obstetrics (FIGO) stage III or IV) at diagnosis (Marsden et al,
2000). These patients have a 5-year survival rate less than 30%,
whereas patients with localised disease at diagnosis have an over
80% survival rate within 5 years (Nguyen et al, 1993; Bast, 2003).
One screening method for ovarian cancer is based on serum
levels of CA125, a tumour-associated glycoprotein of unknown
function. Nowadays, measurement of serum CA125 is considered
essential for monitoring response to treatment (Van der Berg et al,
1988; Tuxen et al, 1995; Rustin et al, 1996) but has a limited value
for general population screening (Tuxen et al, 1995; Zanotti and
Kennedy, 1999). Furthermore, the clinical value of routinely
measuring CA125 during follow-up after initial treatment is
uncertain due to its limitations. One important limitation of
serum CA125 is that its levels are not elevated in 50% of women
with stage I disease and up to 30% of patients with more advanced
disease (Tuxen et al, 1995). Its value as a screening test is even
more uncertain, due to its poor specificity. Serum CA125 is
elevated in a proportion of patients with diverse malignancies,
such as colon, breast, endometrial, lung, liver and pancreatic
tumours (Tuxen et al, 1995). Its levels can also be elevated during
menstruation or pregnancy, as well as in other benign gynaeco-
logical conditions, such as endometriosis, peritonitis or cirrhosis,
especially with ascites production (Tuxen et al, 1995, Meyer and
Rustin, 2000).
Novel methods and markers with improved sensitivity and
specificity are needed for early detection of ovarian cancer (Mills
et al, 2001; Bast, 2003). High-throughput technologies, such as
gene microarrays and proteomic approaches (Rai et al, 2002; Adib
et al, 2004; Hibbs et al, 2004; Lu et al, 2004; Santin et al, 2004;
Zhang et al, 2004), despite their limitations thus far (Diamandis,
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s2004; van der Merwe et al, 2007) have identified several molecular
markers of early disease. Some promising novel ovarian cancer
biomarkers include mesothelin (Huang et al, 2006) and human
epididymis protein 4 (HE4) (Drapkin et al, 2005). In addition,
among the novel markers are the human tissue kallikreins
(kallikrein proteins (KLKs); reviewed in Borgono et al (2004)
and Borgono and Diamandis (2004)).
Kallikreins are a family of 15 secreted serine proteases encoded
by conserved genes, which are tandemly localised on chromosome
19q13.4 (Borgono et al, 2004). The kallikrein proteins are widely
expressed in different tissues, during physiological or pathological
conditions (Borgono et al, 2004; Shaw and Diamandis, 2007).
Furthermore, several kallikreins are coexpressed in tissues or
fluids (Borgono and Diamandis, 2004), suggesting their involve-
ment in proteolytic cascades (Borgono and Diamandis, 2004;
Pampalakis and Sotiropoulou, 2007; Yoon et al, 2007). Clinical
studies have associated kallikreins with several types of cancers
and especially hormone-associated carcinomas, such as breast,
prostate and ovarian (Borgono et al, 2004; Borgono and
Diamandis, 2004). The most recognised kallikrein is KLK3, also
known as prostate-specific antigen, which is an established
biomarker for detecting or monitoring prostate cancer progression
and response to treatment (Magklara et al, 1999; Stephan et al,
2002).
Kallikreins 4, 5, 6, 7, 8, 9, 10, 11, 13, 14 and 15 are highly
expressed in ovarian cancer patients or in ovarian cancer cell lines,
at the mRNA and/or protein level (Tanimoto et al, 1999;
Shvartsman et al, 2003; Borgono et al, 2004; Lu et al, 2004; Ni
et al, 2004; Santin et al, 2004). Four recent studies verified the
overexpression of several kallikreins in ovarian cancer tissues
(Yousef et al, 2003), in disseminated ovarian cancer cells isolated
from ascites fluid of ovarian cancer patients (Oikonomopoulou
et al, 2006b) and in ovarian cancer effusions (Shaw and
Diamandis, 2007; Shih et al, 2007). Some kallikreins, such as
KLK6 (Hoffman et al, 2002) and KLK10 (Luo et al, 2001),
broadcast unfavourable prognosis, whereas others, such as KLK8
(Borgono et al, 2006), have been associated with favourable
prognosis.
In this study, we investigated the serum levels of kallikreins 5, 6,
7, 8, 10 and 11 in relation to the clinical response of ovarian cancer
patients to chemotherapy, the survival outcome (overall and
progression-free survival), as well as the time to progression (TTP)
of the disease. We also included the novel cancer markers B7-H4
(Simon et al, 2007a,b), regenerating protein IV (Reg-IV) and
Spondin-2 (Simon et al, 2007b), which have been reported to be
differentially expressed in ovarian cancer. We performed multi-
parametric analysis, including or excluding CA125, in an effort to
improve the predictive and/or prognostic value of this panel for
ovarian cancer.
MATERIALS AND METHODS
Ovarian cancer patients and specimens
Ninety-eight patients with primary epithelial ovarian cancer were
included in this study, ranging in age from 22 to 77 years, with a
median of 50 years. Patients with stage I–IV ovarian carcinomas
(FIGO stage I: n¼14; stage II: n¼5; stage III: n¼73; stage IV:
n¼6) were included in this study. Patients received the adjuvant
chemotherapy regimen CBDCA/CFA or Taxol/CBDCA.
Among the 95 patients with known clinical response, according
to WHO criteria, 58 (61%) patients had good response, categorised
as complete remission (CR, n¼29), partial remission (PR, n¼21)
or stable disease (SD, n¼8) and 37 patients had poor clinical
response with progressive disease (PD). Among the 50 CR and PR
patients, 27 experienced disease progression, with a median TTP of
6 months (ranging from 3 to 24 months). Patients were monitored
for survival and disease progression with a median follow-up of 24
months (ranging from 2 to 36 months). For 45 patients, the final
end point within the time limits of this study was death.
Blood was drawn before the first chemotherapy and centrifuged
within an hour for serum collection. Serum samples were stored at
 80 1C until analysis. CA125 values were measured for all patients,
utilising a Roche Elecsys method (Roche, Mississauga, ON,
Canada).
Quantification of biomarkers in serum
We quantified protein levels of KLKs 5, 6, 7, 8, 10 and 11, as well as
B7-H4, Reg-IV and Spondin-2, in the serum of ovarian cancer
patients by sandwich-type enzyme-linked immunosorbent assays,
as previously described (Supplementary Table 1, Simon et al,
2007a,b and our unpublished data). KLKs were quantified in
Toronto (Dr Eleftherios P, Diamantis, Mount Sinai Hospital,
Toronto, ON, Canada) and the other three biomarkers at diaDexus
Inc. (San Francisco, CA, USA). All assays are highly sensitive and
specific for each of the measured biomarkers.
Statistical and clinical evaluation of the results
End points For our analysis, we considered four end points: (a)
clinical response, which was subcategorised as good (CR, PR, SD)
vs poor response (PD); (b) overall survival, defined as time from
first chemotherapy to death from any cause; (c) progression-free
survival, defined as time from first chemotherapy to any
progression or death from any cause; and (d) time from the first
chemotherapy to progression (TTP) among CR and PR patients.
For TTP, death was a competing risk and was treated as censored
data.
Biomarkers Serum samples were obtained before therapy (base-
line specimen; c0) and before each chemotherapy cycle (c1–cn).
The markers B7-H4, Spondin-2 and Reg-IV were measured only at
c0, due to limited sample availability. As 59 patients had at least
two measurements for each marker and 32 patients had at least
three measures available, we considered marker concentration
before and after the first treatment cycle (c0,c 1) in logarithmic
scale, relative changes in tumour marker after the first and the
second cycle of chemotherapy (rc1¼log(c0/c1); rc2¼log(c1/c2))
and sometimes the ratios of these changes, (rc1/rc2), when sample
sizes were deemed sufficient.
The relationships between biomarkers with patient and tumour
characteristics were examined with the Kruskal–Wallis test, a non-
parametric method for examining differences among multiple
groups. Spearman’s rank correlation coefficient was utilised to
assess the correlations among biomarkers. The primary outcome
for survival analyses was the progression-free survival, defined as
the time from diagnosis to ovarian cancer recurrence or death
from any cause. Patients, who were alive and did not meet any
events, as defined by these end points, were censored at the time
the last vital status was ascertained. Kaplan–Meier curves were
utilised to present the survival probabilities as a function of time
among groups of patients, defined by the tertile of the marker
values, and log-rank tests were utilised to examine the overall
difference among the curves. Cox regression model was applied to
evaluate the hazard ratios (HRs) of biomarkers on overall and
progression-free survival. Clinical parameters, including age and
stage of disease, were adjusted in multivariate Cox proportional
hazard models. Logistic regression was performed to calculate the
odds ratio (OR) that defines the relation between biomarkers and
response to therapy, where the outcome is response (partial
response or complete response) vs no response (no change or
progression). Both HR and OR were calculated on log-transformed
biomarkers and were represented with their 95% confidence
interval (95% CI) and two-sided P-values.
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sTo further evaluate the diagnostic or prognostic usefulness of
the markers for dichotomous classification, we considered
receiver-operating characteristic (ROC) curve analysis. If by
convention larger values of a biomarker were associated with
adverse outcome, a cutoff point was utilised to define a positive
marker-based test result, that is positive if the marker value
exceeded a certain cutoff point. For a marker measured on
continuous scales, the ROC curve was evaluated for all possible
cutoff points. For binary outcome, that is response to chemo-
therapy, the ROC curve quantified the discriminatory ability of a
marker for distinguishing between responders and non-respon-
ders. For TTP analysis, where the disease outcome is not
concurrent with the test and the accuracy is a function of time,
time-dependent ROC techniques for censored survival times were
considered (Heagerty et al, 2000). We compared the true positive
fraction, P (marker4cutoff point; death within t year) and false
positive fraction, P (marker4cutoff point; survived beyond
t year), across all possible cutoff points, and for t equal to 1 year
and 5 years, respectively. For each ROC curve, we calculated the
area under the curve (AUC), which ranges from 0.5 (for a non-
informative marker) to 1 (for a perfect marker) and corresponds to
the probability that a randomly selected patient who dies within
t years has a higher marker value than a randomly selected patient
who survived. Bootstrap method was utilised to calculate the
CIs for AUC.
The ROC analysis was first conducted on individual markers
and then in combination to explore the potential that a panel of
markers can provide improved performance. We considered an
algorithm that renders a single composite score using the linear
predictor fitted from a binary regression model. This algorithm
has been justified to be optimal under the linearity assumption
(Eguchi and Copas, 2002; McIntosh and Pepe, 2002) in the sense
that ROC curve is maximised (i.e., best sensitivity) at every
threshold value. In particular, a weighted logistic regression which
is appropriate for censored failure time data was utilised (Zheng
et al, 2006) for deriving the prognostic index. A stepwise
regression procedure was utilised to select markers within the
panel, sometimes along with clinical variables.
As an independent validation series was not available for this
study, the predictive accuracy of the composite scores was
evaluated based on re-sampling of the original data. Specifically,
we randomly split the data into a learning set and a test set. The
learning set included two of three of the observations and the test
set one of three of the observations. Using the learning set, we first
performed model selection from which the final selected model
gave rise to the linear combination rule. We then calculated two
ROC curves for the linear score, one using data from the learning
set and the other from the training set. The vertical differences
between the two ROC curves gave the overestimation of the
sensitivities at given specificities. The whole procedure was
repeated 200 times and these differences were averaged to yield
an estimate of the expected overestimation. For each type of the
ROC analyses mentioned above, we present both the original ROC
curves and the ROC curves that are corrected for overestimation.
All statistical analyses were performed using software SAS 9.1
(SAS Institute Inc., Cary, NC, USA) and S-PLUS 7.0 (Insightful
Corp., Seattle, WA, USA).
RESULTS
Associations of biomarkers with clinicopathological
factors
Significant correlations (Po0.05) were observed between most of
the biomarkers, in particular among CA125 and all markers except
KLK7 (Supplementary Table 2). Supplementary Table 3 presents
distributions of individual markers, stratified by age and stage.
Lower levels of CA125, B7-H4 and Spondin-2 were significantly
associated with older age (all Po0.05), whereas higher values of
markers tended to be associated with higher clinical stages for
CA125, KLK5, KLK6, KLK10, KLK11, B7-H4 and Spondin-2
(all Po0.05).
Associations of biomarkers with response to chemotherapy
We considered the association of serially measured biomarkers
with clinical response to chemotherapy (good: CR, PR or SD vs
poor: PD) using logistic regression models (Table 1). Univariately,
statistically significant predictors of response included baseline
measures of CA125, KLK6, KLK8, KLK10, B7-H4 and Reg-IV (all
Po0.05), with a lower baseline level of the marker associated with
favourable response. In addition, changes in CA125 from first
chemotherapy cycle compared to baseline also appeared to predict
response (OR¼1.84, 95% CI (1.12, 3.03), P¼0.017). Similarly,
rapid decreases in KLK5 level after the first chemotherapy cycle
also appeared to associate with favourable response (OR¼1.86,
95% CI (1.09, 3.18), P¼0.022). As age and stage were not
significantly related to chemotherapy response, we did not
consider further multivariate regression models adjusting for age
or stage of disease.
Receiver-operating characteristic curve analysis was utilised to
evaluate the clinical usefulness of these markers for predicting
response to chemotherapy. When considered separately, these
markers only had moderate discriminatory capacity for separating
good from poor responders. For example, the baseline level of
KLK6 had an AUC of 0.69 (95% CI (0.58, 0.80)) (Table 1), whereas
changes of CA125 after the first cycle had an AUC of 0.69 (95% CI
(0.58, 0.81)). We further explored if the combination of a panel of
markers could improve this diagnostic accuracy. We employed a
stepwise model selection procedure that took all the baseline
markers into consideration. Using the linear predictors from the
final model involving KLK5, KLK6, KLK7 and B7-H4, we obtained
an ROC curve with an AUC of 0.77 (95% CI (0.68, 0.87)). However,
due to sample-size limitation, when correcting for the uncertainty
in both model selection and ROC-estimation cross-validation
procedure, the analysis resulted in a corrected AUC of only 0.63
(Figure 1A). We also considered building a logistic regression
model using information on both baseline concentration and
relative changes after each chemotherapy cycle. The final selected
multivariate model, which included baseline measures of CA125,
KLK5 KLK7 and the relative change at the first chemotherapy for
CA125, resulted in an ROC curve that had an AUC of 0.82 (95% CI
(0.73, 0.93)). However, due to limited sample size and even greater
uncertainty involved in the model-fitting procedure, the corrected
AUC was 0.62 (Figure 1B). Therefore, with the current sample
size, we cannot conclude if including longitudinal information can
improve the predictive accuracy.
Associations of biomarkers with overall survival
The Kaplan–Meier estimates of time to overall survival for
patients stratified in three risk groups, as defined by tertiles of
the level of an individual marker, indicated that many of the
markers have good prognostic values (Supplementary Figure 1). In
addition, we also saw good separations of Kaplan–Meier curves
when patients were classified by both stage (I/II vs III/IV) and
marker concentrations (upper, defined as 4median value; vs
lower, defined as omedian value) (Supplementary Figure 1),
suggesting that these markers may provide useful prognostic
information in addition to clinical staging criteria.
The unadjusted and adjusted HRs estimated from Cox propor-
tional hazard models are presented in Table 2. Higher values of
baseline measures of CA125, KLK5, KLK6, KLK10, B7-H4 and
Spondin-2 were all significantly associated with worse overall
survival. For example, the HR for Spondin-2 was 2.67 (95% CI
Multiparametric biomarker panels for ovarian cancer
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s(1.43, 4.96), P¼0.002). The prognostic values of many of the
kallikreins, B7-H4 and Spondin-2 were stronger than those of
CA125 (based on HR values), which had a HR of 1.34 (95% CI
(1.17, 1.53), Po0.001). Adjustment for clinical variables including
age, stage and response to chemotherapy was also performed.
When considering this multivariate model, some markers became
insignificant but some of them retained their significance. For
example, an HR of 1.28 (95% CI (1.02, 1.60), P¼0.034) was
observed for KLK5 and 1.69 (95% CI (1.14, 2.49), P¼0.008) for
B7-H4, indicating that these two markers may provide additional
prognostic value beyond age, clinical stage or response to
chemotherapy. Changes in some marker concentrations after each
Table 1 Univariate logistic regression for chemotherapy response (good vs poor)
Clinical variable N (%) OR CI P
Age (years)
p50 52 (54%) 1
450 45 (46%) 1.09 (0.47, 2.51) 0.842
Stage
I or II 19 (19%) 1
III or IV 79 (81%) 0.89 (0.32, 2.53) 0.833
Poor Good
Markers N Mean (s.d.)
a N Mean (s.d.) P**
CA125
Baseline (c0) 37 5.488 (2.227) 57 4.401 (1.854) 0.023
rc1¼log(c0/c1) 34 0.121 (1.069) 53 0.753 (1.105) 0.003
rc2¼log(c1/c2) 20 0.339 (0.473) 34 0.587 (1.191) 0.986
rc1/rc2 20 0.181 (1.215) 33 0.223 (1.338) 0.279
KLK5
Baseline (c0)3 7  1.776 (1.629) 58  1.657 (1.03) 0.466
rc1¼log(c0/c1)3 5  0.141 (1.016) 54 0.372 (0.903) 0.016
rc2¼log(c1/c2) 22 0.111 (0.482) 34 0.217 (0.584) 0.860
rc1/rc2 22  0.141 (1.216) 34 0.134 (1.149) 0.140
KLK6
Baseline (c0) 37 3.077 (0.808) 58 2.562 (0.743) 0.002
rc1¼log(c0/c1) 35 0.175 (0.668) 53 0.084 (0.645) 0.932
rc2¼log(c1/c2) 22 0.036 (0.568) 34 0.082 (0.466) 0.827
rc1/rc2 22 0.286 (1.191) 34 0.003 (0.927) 0.627
KLK7
Baseline (c0) 37 1.283 (0.501) 58 1.071 (0.579) 0.0747
rc1¼log(c0/c1) 35 0.013 (0.374) 53 0.012 (0.537) 0.956
rc2¼log(c1/c2) 22 0.016 (0.291) 34 0.078 (0.319) 0.568
rc1/rc2 22 0.01 (0.581) 34  0.16 (0.557) 0.450
KLK8
Baseline (c0) 37 2.54 (0.653) 58 2.246 (0.569) 0.017
rc1¼log(c0/c1) 35 0.062 (0.466) 53 0.019 (0.511) 0.673
rc2¼log(c1/c2)2 2  0.013 (0.405) 34 0.114 (0.364) 0.302
rc1/rc2 22 0.07 (0.737) 34  0.15 (0.717) 0.227
KLK10
Baseline (c0) 37 1.463 (0.864) 58 1.022 (0.947) 0.013
rc1¼log(c0/c1) 35 0.126 (0.511) 53 0.198 (0.74) 0.805
rc2¼log(c1/c2) 22 0.073 (0.218) 34 0.076 (0.351) 0.481
rc1/rc2 22 0.073 (0.709) 34 0.108 (0.7) 0.663
KLK11
Baseline (c0) 36 0.052 (0.774) 57  0.199 (0.737) 0.196
rc1¼log(c0/c1) 34 0.001 (0.632) 53 0.192 (0.677) 0.058
rc2¼log(c1/c2) 22 0.129 (0.358) 34 0.066 (0.306) 0.574
rc1/rc2 21 0.03 (0.901) 34 0.176 (0.527) 0.161
B7-H4
Baseline (c0) 35 1.216 (1.006) 52 0.719 (0.976) 0.009
Reg-IV
Baseline (c0)3 4  0.246 (0.517) 49  0.518 (0.521) 0.027
Spondin-2
Baseline (c0) 34 4.398 (0.551) 49 4.209 (0.542) 0.101
CI¼confidence interval; OR¼odds ratio.
aLogarithmically transformed values. **Wilcoxon Rank Sum test.
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schemotherapy treatment cycle also appeared to predict survival. In
particular, rc1 of KLK6 significantly predicted time to survival in
the univariate Cox regression models (HR¼1.77, 95% CI (1.07,
2.95), P¼0.028); however, none of the subsequent measurements
remained a significant independent predictor in the multivariate
model (with the exception of KLK6 rc1/rc2 ratio).
To assess whether the markers have good capacity in
discriminating between subjects who progress before a given time
t and those who survive beyond t, the time-dependent ROC
method was utilised to evaluate the prognostic accuracy of the
biomarkers. We plotted ROC curves at 1 year to investigate
whether they have the accuracy to separate short-term survivors
(failed by 1 year vs alive beyond 1 year). Although univariately, the
predictive accuracy of each individual marker was quite low (data
not shown), it was interesting to see whether we could identify a
marker panel that would offer improved prognostic accuracy. We
utilised a weighted logistic regression for survival data that aimed
to directly find a linear combination of markers with which the
area under the time-dependent ROC curve is maximised at each t.
We found that a combination of markers may have the potential
for improved prognostic accuracy. A linear combination rule
considering KLK7, KLK10, B7-H4 and Spondin-2 yielded an ROC
curve for survival at 1 year after chemotherapy with an AUC of
0.89 (95% CI (0.81, 0.96)) (Figure 2A). After correcting for
overfitting, the prognostic performance was retained with an AUC
of 0.74. Addition of clinical data (age, stage and response to
chemotherapy) to the selected marker panel further improved the
unadjusted AUC to 0.94 (Figure 2B). No improvement was
observed for 2-year mortality even with a combination of a panel
of markers (data not shown). These results suggest that there may
be a good potential for the panel of markers to achieve good short-
term (within 1-year) prognostic performance.
Associations of biomarkers with progression-free survival
We performed Kaplan–Meier analysis of TTP for our patient
groups, concluding that many of the markers have prognostic
values (Supplementary Figure 2). The curves also showed a good
separation when patients were divided into groups, according to
marker concentrations (upper, defined as 4median value; vs
lower, defined as omedian value).
The unadjusted HRs for progression-free survival are listed in
Table 3. Higher values of baseline measures of CA125, KLK5,
KLK6, KLK10, KLK11, B7-H4 and Spondin-2 were all significantly
associated with worse progression-free survival. For example, the
HR for Spondin-2 was 2.21 (95% CI (1.3, 3.76), P¼0.003). The
prognostic values of many of the kallikreins, as well as of the
markers B7-H4 and Spondin-2, were stronger than those of CA125
(based on HR values). Adjustment for clinical variables, including
age, stage and response to chemotherapy, resulted in HRs of 1.23
(95% CI (1.07, 1.42), P¼0.004) for CA125, 1.33 (95% CI (1.08,
1.64), P¼0.008) for KLK5, 1.44 (95% CI (1.06, 1.97), P¼0.022) for
KLK10, 1.67 (95% CI (1.10, 2.55), P¼0.017) for KLK11 and 1.71
(95% CI (1.25, 2.35), P¼0.001) for B7-H4. Changes in marker
concentrations after the chemotherapy cycles also appeared to
predict progression-free survival. In particular, rc1 of CA125,
KLK10 and KLK11 significantly predicted TTP in the multivariate
Cox regression models (all P-values o0.05) that adjust for age,
stage and chemotherapy response, indicating that decreases in
these markers after the first chemotherapy cycle may be associated
with an adverse event in the future.
We further evaluated the prognostic accuracy for different risk
classifications of a panel of biomarkers. A linear combination of
some markers (CA125, KLK7, KLK8 and KLK10 at the baseline)
resulted in an ROC curve at 1 year, after initiation of treatment,
with AUC 0.77 (95% CI (0.70, 0.90)). However, when corrected for
overfitting, the AUC for corrected ROC curve was reduced to 0.62
(data not shown).
Associations of biomarkers with TTP among CR and PR
patients
For the 50 patients who were in CR (n¼29) or PR (n¼21), we
examined whether the markers can predict their times to
progression. We investigated this question by analysing the
predictive value for time to cancer progression for each individual
biomarker. The results of the Cox analyses are summarised in
Table 4. Younger (o50 years old) or later stage (stages III and IV)
patients were associated with higher risk of progression, although
the effect of age was only marginally significant. Except for KLK7
and Reg-IV, higher concentrations of all other markers at baseline
were associated with higher risk of progression. For example,
CA125 had an HR of 1.71 (95% CI (1.37, 2.13), Po0.001), whereas
KLK5 had an HR of 2.44 (95% CI (1.59, 3.75), Po0.001) and
Spondin-2 had an HR of 3.35 (95% CI (1.54, 7.26), P¼0.002). In
addition, changes after first chemotherapy from baseline of CA125,
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Figure 1 ROC curves for chemotherapy response using marker panels. ROC curves for the ‘combined’ marker, without (‘original’, solid line) and with
correction for overfitting (‘corrected’, dashed line). The correction for overfitting was done by the cross-validation procedure described under Materials and
methods. (A) Combination using only baseline values (c0) of KLK5, KLK6, KLK7 and B7-H4. (B) Combination using baseline values (c0) of CA125, KLK5 and
KLK7 and relative changes (rc1¼log(c0/c1)) of CA125 from baseline to the first chemotherapy. Data for good vs poor response are further described in
Table 1 and the combined model is described in Supplementary Table 4.
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sTable 2 Cox regression for overall survival outcome
Univariate Multivariate
Clinical variable N (%) HR CI P HR CI P
Age (years)
p50 52 (54%) 1 1
450 45 (46%) 0.56 (0.3, 1.06) 0.074 0.63 (0.33, 1.21) 0.166
Stage
I or II 19 (19%) 1 1
III or IV 79 (81%) 2.49 (0.98, 6.34) 0.056 2.04 (0.78, 5.36) 0.146
Chemotherapy response
Poor 37 (37%) 1 1
Good 58 (61%) 0.18 (0.09, 0.35) o0.001 0.19 (0.1, 0.37) o0.001
Markers
CA125
Baseline (c0) 97 1.34 (1.17, 1.53) o0.001 1.16 (0.98, 1.38) 0.086
rc1¼log(c0/c1) 90 0.96 (0.71, 1.31) 0.792 1.06 (0.75, 1.51) 0.732
rc2¼log(c1/c2) 57 1.36 (0.94, 1.96) 0.102 1.49 (0.94, 2.36) 0.087
rc1/rc2 56 1.01 (0.69, 1.47) 0.967 1.08 (0.73, 1.6) 0.685
KLK5
Baseline (c0) 98 1.33 (1.03, 1.71) 0.028 1.28 (1.02, 1.6) 0.034
rc1¼log(c0/c1) 92 0.91 (0.64, 1.27) 0.571 1.04 (0.73, 1.48) 0.827
rc2¼log(c1/c2) 59 1.66 (0.87, 3.16) 0.125 1.63 (0.76, 3.51) 0.208
rc1/rc2 59 0.95 (0.68, 1.34) 0.780 1.06 (0.74, 1.53) 0.748
KLK6
Baseline (c0) 98 2.09 (1.4, 3.11) o0.001 1.36 (0.88, 2.12) 0.168
rc1¼log(c0/c1) 91 1.77 (1.07, 2.95) 0.028 1.49 (0.85, 2.6) 0.160
rc2¼log(c1/c2) 59 0.89 (0.38, 2.08) 0.786 0.53 (0.24, 1.19) 0.125
rc1/rc2 59 1.57 (1.01, 2.45) 0.044 1.61 (1.08, 2.4) 0.020
KLK7
Baseline (c0) 98 0.86 (0.5, 1.48) 0.595 0.59 (0.33, 1.08) 0.088
rc1¼log(c0/c1) 91 0.9 (0.46, 1.75) 0.753 0.86 (0.39, 1.91) 0.713
rc2¼log(c1/c2) 59 0.54 (0.15, 2.01) 0.359 0.71 (0.19, 2.7) 0.614
rc1/rc2 59 1.51 (0.7, 3.26) 0.289 1.25 (0.58, 2.68) 0.570
KLK8
Baseline (c0) 98 1.58 (0.95, 2.64) 0.080 1.16 (0.69, 1.94) 0.586
rc1¼log(c0/c1) 91 1.13 (0.57, 2.23) 0.727 0.97 (0.48, 2) 0.942
rc2¼log(c1/c2) 59 0.66 (0.23, 1.9) 0.443 1.48 (0.47, 4.62) 0.503
rc1/rc2 59 1.33 (0.78, 2.28) 0.289 0.99 (0.55, 1.78) 0.975
KLK10
Baseline (c0) 98 1.47 (1.11, 1.96) 0.008 1.3 (0.89, 1.9) 0.176
rc1¼log(c0/c1) 91 1.04 (0.65, 1.66) 0.880 1.13 (0.64, 2.01) 0.669
rc2¼log(c1/c2) 59 1.08 (0.3, 3.89) 0.901 0.57 (0.11, 2.95) 0.505
rc1/rc2 59 1.31 (0.67, 2.54) 0.432 1.56 (0.83, 2.93) 0.169
KLK11
Baseline (c0) 95 1.46 (0.93, 2.28) 0.097 1.18 (0.72, 1.91) 0.513
rc1¼log(c0/c1) 89 0.98 (0.61, 1.57) 0.917 1.07 (0.63, 1.79) 0.811
rc2¼log(c1/c2) 59 1.38 (0.45, 4.18) 0.572 1.09 (0.36, 3.33) 0.881
rc1/rc2 57 1.14 (0.64, 2.04) 0.659 1.22 (0.73, 2.03) 0.453
B7-H4
Baseline (c0) 89 2.04 (1.48, 2.81) o0.001 1.69 (1.14, 2.49) 0.008
Reg-IV
Baseline (c0) 85 1.56 (0.89, 2.74) 0.119 1 (0.52, 1.92) 0.996
Spondin-2
Baseline (c0) 85 2.67 (1.43, 4.96) 0.002 1.65 (0.81, 3.35) 0.167
CI¼confidence interval; HR¼hazard ratio.
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Combining CA125, KLK7, KLK8 and Spondin-2 at baseline yielded
good prognostic accuracy for predicting patients with progression
by 1 year: the area under the ROC curve at 1 year after treatment
was 0.87 (95% CI (0.77, 1.00)), but was reduced to 0.65 when
potential overfitting was adjusted (Figure 3). Although there is
potential that the prognostic accuracy could be further improved
using longitudinal measures, potential of overfitting is also
significant, given our sample size. We therefore did not explore
this further.
In summary, the regression models utilised for ROC curve
analysis for a panel of markers with different outcomes are
presented in Supplementary Table 4.
DISCUSSION
Ovarian cancer detection, prognosis and response to treatment
are currently based on quantification of serum levels of CA125 and
imaging modalities (Van der Berg et al, 1988; Marsden et al, 2000;
Meyer and Rustin, 2000). However, the clinical value of CA125
as a marker of ovarian cancer is low, due to its expression in
non-malignant or non-ovarian malignant conditions (Tuxen et al,
1995; Meyer and Rustin, 2000). Serum CA125 is presently
considered as a marker of response to treatment rather than a
screening/diagnostic marker (Van der Berg et al, 1988; Tuxen et al,
1995; Rustin et al, 1996; Zanotti and Kennedy, 1999). As part
of the quest to identify useful biomarkers for detection and
management of ovarian carcinoma, the idea of multimarker
analysis has been adopted by many groups (Bose and Mukherjea,
1994; Zhang et al, 2004). Thus far, increases in the diagnostic
sensitivity of CA125 by using marker panels have been moderate
(5–10%), often at the expense of decreases in specificity, and vice
versa (Tuxen et al, 1995; Meyer and Rustin, 2000; Bast, 2003; Zhang
et al, 2004).
Members of one family of cancer-related markers, the kallikrein
serine protease family, have been associated with either favourable
or unfavourable prognostic value in ovarian cancer or they are
candidate diagnostic markers (Borgono et al, 2004, 2006; Borgono
and Diamandis, 2004; Shan et al, 2006; McIntosh et al, 2007). The
clinical applicability of the other three candidate ovarian cancer
markers included in this study, B7-H4 (Simon et al, 2007a,b),
Reg-IV and Spondin-2 (Simon et al, 2007b), is still unknown.
We found significant correlations between the serological
markers used in this study. For example, CA125 correlated
significantly with all the markers studied, except KLK7 (Supple-
mentary Table 2). These data are in agreement with previous
observations (Borgono et al, 2004; Borgono and Diamandis, 2004).
Utilisation of such biomarkers in multiparametric analyses may
prove beneficial for ovarian cancer diagnosis, prognosis and
prediction of therapeutic response. As a proof of this principle, in a
recent study, a panel of kallikreins (KLKs 4, 5, 6, 7, 8, 10, 11, 13 and
14) was able to confidently discriminate cancerous from benign
effusions, with an area under the ROC curve of 0.99, and ovarian
cancer from other cancer groups with an AUC of 0.96 (Shih et al,
2007).
In our study, the predictive power of many markers for overall
(Table 2) and progression-free survival (Table 3) at univariate
analysis was encouraging. For example, CA125, KLKs 5, 6, 10,
B7-H4 and Spondin-2 baseline values (c0) predicted a worse overall
survival (Table 2) and CA125, KLKs 5, 6, 10, 11, B7-H4 and
Spondin-2 baseline values (c0) a worse progression-free survival of
ovarian cancer patients (Table 3). Many of these markers were
independent of clinical parameters, such as age, FIGO stage or
response to treatment, when multivariate analysis was performed.
Similarly to the previous study for ovarian cancer detection
(Shih et al, 2007), we considered panels of these markers to predict
patient survival. Such a panel, which included KLK7, KLK10,
B7-H4 and Spondin-2 baseline values (c0), was significantly predic-
tive of 1-year survival post-therapy, with an AUC of 0.89 (Figure 2A).
Moreover, our findings suggested that high baseline values (c0)
of markers (CA125, KLKs 6, 8, 10, B7-H4 and Reg-IV), as well as
changes of CA125 and KLK5 after the first chemotherapy cycle
(rc1), individually predicted an unfavourable response to chemo-
therapy and a higher risk for disease progression (Table 1). A
panel of markers comprising KLK5, KLK6, KLK7 and B7-H4
baseline levels (c0) resulted in an improved AUC of 0.77 for
predicting response to chemotherapy (Figure 1A).
Baseline values (c0) of all markers, except of KLK7 and Reg-IV,
were also significant predictors of TTP among the group of
responders to chemotherapy (Table 4). Combination of CA125,
KLK7, KLK8 and Spondin-2 baseline levels predicted patients who
would progress within 1 year, with an ROC curve of 0.87 (Figure 3).
Notably, thirty-one of the patients included in this study had a
baseline serum CA125 concentration that was close to or below the
cutoff point of 30Uml
 1 and remained non-informative (no
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Figure 2 ROC curves for overall survival at 1-year post-chemotherapy, using a panel of biomarkers, without (‘original’, solid line) and with correction for
overfitting (‘corrected’, dashed line). The correction for overfitting was done by the cross-validation procedure described under Materials and methods. Data
for overall survival are further described in Table 2 and the combined model is described in Supplementary Table 4. (A) Combination using baseline values
(c0) of KLK7, KLK10, B7-H4 and Spondin-2. (B) Combination using baseline values (c0) of KLK5, KLK7, KLK10 and B7-H4 and the clinical parameters age,
stage and response to chemotherapy.
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Univariate Multivariate
Clinical variable N (%) HR CI P HR CI P
Age (years)
p50 52 (54%) 1 1
450 45 (46%) 0.59 (0.35, 1) 0.049 0.68 (0.4, 1.17) 0.166
Stage
I or II 19 (19%) 1 1
III or IV 79 (81%) 3.43 (1.47, 8.01) 0.004 2.98 (1.26, 7.03) 0.013
Chemotherapy response
Poor 37 (37%) 1 1
Good 58 (61%) 0.56 (0.33, 0.94) 0.030 0.62 (0.37, 1.06) 0.079
Markers
CA125
Baseline (c0) 97 1.31 (1.17, 1.46) o0.001 1.23 (1.07, 1.42) 0.004
rc1¼log(c0/c1) 90 1.4 (1.09, 1.78) 0.007 1.31 (1.01, 1.69) 0.042
rc2¼log(c1/c2) 57 1.56 (1.18, 2.05) 0.002 1.47 (1.09, 1.98) 0.013
rc1/rc2 56 0.92 (0.67, 1.27) 0.605 0.94 (0.7, 1.28) 0.715
KLK5
Baseline (c0) 98 1.41 (1.14, 1.74) 0.001 1.33 (1.08, 1.64) 0.008
rc1¼log(c0/c1) 92 1.19 (0.9, 1.59) 0.224 1.16 (0.88, 1.54) 0.301
rc2¼log(c1/c2) 59 2.16 (1.28, 3.63) 0.004 1.74 (0.97, 3.1) 0.062
rc1/rc2 59 0.95 (0.71, 1.27) 0.728 1.06 (0.78, 1.45) 0.701
KLK6
Baseline (c0) 98 1.54 (1.11, 2.15) 0.011 1.23 (0.85, 1.77) 0.265
rc1¼log(c0/c1) 91 1.56 (1.01, 2.39) 0.044 1.18 (0.74, 1.9) 0.491
rc2¼log(c1/c2) 59 1.2 (0.54, 2.65) 0.659 0.8 (0.37, 1.72) 0.560
rc1/rc2 59 1.25 (0.83, 1.87) 0.292 1.32 (0.91, 1.89) 0.140
KLK7
Baseline (c0) 98 1.19 (0.74, 1.91) 0.478 1.03 (0.64, 1.66) 0.897
rc1¼log(c0/c1) 91 1.33 (0.73, 2.45) 0.354 1.28 (0.68, 2.4) 0.441
rc2¼log(c1/c2) 59 0.69 (0.23, 2.09) 0.509 0.68 (0.22, 2.08) 0.497
rc1/rc2 59 1.32 (0.69, 2.53) 0.408 1.34 (0.7, 2.56) 0.376
KLK8
Baseline (c0) 98 1.53 (0.98, 2.39) 0.061 1.33 (0.84, 2.11) 0.231
rc1¼log(c0/c1) 91 1.3 (0.72, 2.35) 0.380 1.21 (0.65, 2.24) 0.549
rc2¼log(c1/c2) 59 0.91 (0.37, 2.25) 0.834 1.28 (0.47, 3.5) 0.627
rc1/rc2 59 1.11 (0.69, 1.79) 0.664 1.05 (0.62, 1.78) 0.847
KLK10
Baseline (c0) 98 1.6 (1.21, 2.12) 0.001 1.44 (1.06, 1.97) 0.022
rc1¼log(c0/c1) 91 1.6 (1.12, 2.27) 0.010 1.56 (1.04, 2.33) 0.030
rc2¼log(c1/c2) 59 3.06 (0.86, 10.87) 0.084 1.84 (0.46, 7.39) 0.391
rc1/rc2 59 1.07 (0.59, 1.94) 0.817 1.2 (0.67, 2.17) 0.536
KLK11
Baseline (c0) 95 1.94 (1.33, 2.83) 0.001 1.67 (1.1, 2.55) 0.017
rc1¼log(c0/c1) 89 1.7 (1.17, 2.46) 0.005 1.56 (1.04, 2.34) 0.031
rc2¼log(c1/c2) 59 2.22 (0.91, 5.44) 0.081 1.5 (0.59, 3.84) 0.396
rc1/rc2 57 1.34 (0.81, 2.22) 0.248 1.43 (0.87, 2.35) 0.156
B7-H4
Baseline (c0) 89 1.96 (1.49, 2.59) o0.001 1.71 (1.25, 2.35) 0.001
Reg-IV
Baseline (c0) 85 1.07 (0.65, 1.76) 0.804 0.89 (0.52, 1.53) 0.671
Spondin-2
Baseline (c0) 85 2.21 (1.3, 3.76) 0.003 1.52 (0.83, 2.76) 0.173
CI¼confidence interval; HR¼hazard ratio.
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patients, a few of the examined markers, for example KLK6
(OR¼0.42; P¼0.004), KLK8 (OR¼0.44; P¼0.026), KLK10
(OR¼0.59; P¼0.03), B7-H4 (OR¼0.60; P¼0.03) and Reg-IV
(OR¼0.36; P¼0.027) appeared to be associated with response to
chemotherapy. These data suggest that some markers may be
superior or complement CA125 for predicting response to
chemotherapy treatment.
It has been reported that the chemopreventive agent
a-difluoromethylornithine is not able to efficiently block expres-
sion of many tumorigenesis-related genes, including kallikrein 6,
in activated Ki-ras-expressing Caco-2 cells (Ignatenko et al, 2004).
In this regard, it is possible that kallikreins may have a function in
chemotherapy-resistant tumours, as it has already been proposed
for kallikreins 3 (Foekens et al, 1999) and 10 (Luo et al, 2002)
in breast cancer and kallikrein 4 in ovarian cancer (Xi et al, 2004).
A similar role has also been proposed for Reg-IV in gastric
tumours (Mitani et al, 2007). The markers included in this study
should be, therefore, validated with a larger sample size to
establish their applicability for ovarian cancer prognosis and
response to chemotherapy.
Amongst the markers evaluated in this study, the members of
the kallikrein family have been reported to cleave extracellular
matrix proteins associated with tissue remodelling (Borgono and
Diamandis, 2004; Ghosh et al, 2004; Michael et al, 2005), as well as
activate or disarm protease-activated receptors (Oikonomopoulou
et al, 2006a, Ramachandran and Hollenberg, 2007). Furthermore,
they have been examined as putative modulators of neovascular-
isation (Aimes et al, 2003) and potential activators of molecules
associated with tumour growth, survival, invasion or metastasis
(Yoi et al, 1979; Frenette et al, 1997; Takayama et al, 2001; Petraki
et al, 2002; Borgono and Diamandis, 2004). In this regard,
kallikreins may be valuable targets for developing novel cancer
therapeutic interventions.
Supplementary Information accompanies the paper on British
Journal of Cancer website (http://www.nature.com/bjc)
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curve calculated using cross-validation to correct for overfitting (AUC with
an asterisk, dashed line). Combined markers for included baseline measures
(c0) of CA125, KLK7, KLK8 and Spondin-2 are further described in
Supplementary Table 4.
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